Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LIG1 | P18858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10328645 | 0.77 | LMNA (0.43) | TSHRTP53PTGER4ALDH1A1MAPT | |
| SCHEMBL3267104 | 0.77 | RAB9A (0.55) | GAATSHRKMT2APTGS1PTGS2 | |
| SCHEMBL10328638 | 0.77 | PTGER4 (0.38) | KMT2ACA12CA1CA9PTGER4 | |
| SCHEMBL6900481 | 0.76 | MEN1 (0.42) | TSHRTP53KMT2ACA9PTGER4 | |
| SCHEMBL1037140 | 0.76 | PTGER4 (0.52) | KMT2APTGER4KDM4EALDH1A1POLB | |
| SCHEMBL10328642 | 0.76 | PTGER4 (0.37) | KMT2APTGS1PTGER4KDM4ESMN1; SMN2 | |
| SCHEMBL13323728 | 0.76 | ALDH1A1 (0.38) | GAAKMT2APTGER4KDM4EALDH1A1 | |
| SCHEMBL10328650 | 0.75 | RAB9A (0.50) | GAAKMT2APTGER4MAPTHPGD | |
| SCHEMBL10328605 | 0.75 | MEN1 (0.48) | TSHRTP53KMT2AALDH1A1HPGD | |
| SCHEMBL3217997 | 0.74 | SMN1; SMN2 (0.55) | PTGS2CA12CA1CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| US-8748483-B2 | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | SANOFI (FR) | 2014-06-10 | — | — | US | disclosed |
| EP-2120923-B1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI SA (FR) | 2012-07-18 | — | — | EP | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2010-06-10 | — | — | US | disclosed |
| WO-2008086949-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144862-A1 | USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME | PC, PCK1, PDK4 | GAA 2202/4885TSHR 1521/4885TP53 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.